Shareholders' Inquiry Transfer Plan
Filed with SSE · · 5 pages · Chinese
Summary by 6ix AI
The plan involves the transfer of a significant number of shares by certain shareholders prior to the company's initial public offering. The shareholders involved have committed to ensuring the accuracy and completeness of the information provided in the filing.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shenzhen Chipscreen Biosciences Co. Ltd. on 6ix
Earlier from Shenzhen Chipscreen Biosciences
- Announcement on Voluntary Disclosure of Approval of Chiglitazar Sodium for Market Release by the Pharmaceutical Administration Bureau, Macao SAR
- Announcement on Receipt of the "Decision on the Examination of an Invalidity Declaration Request" from the China National Intellectual Property Administration
- Announcement on Adjusting the Conversion Price of "Chipscreen Convertible Bonds" Due to the Implementation of the 2025 Annual Profit Distribution and Resumption of Trading After Conversion Suspension
- Announcement on Convening the Q1 2026 Performance Briefing
- Report for Q1 2026
Later from Shenzhen Chipscreen Biosciences
- Indicative Announcement on Pricing for Shareholders' Inquiry-based Transfer
- Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer Multiple
- Announcement on Progress in Repurchasing Shares
- Announcement on Follow-up Credit Rating Results of "Chipscreen Convertible Bonds"
- Announcement on Conversion Result of Convertible Bonds and Share Changes
Follow Shenzhen Chipscreen Biosciences into a list and get an email when it puts out news.
Follow Shenzhen Chipscreen Biosciences